Seelos therapeutics retains canaccord genuity in connection with review of potential partnerships and collaborations

New york , oct. 17, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has retained canaccord genuity to assist in its ongoing review of potential partnerships, collaborations, and similar opportunities. there can be no assurance that the review process will result in the entry into any partnerships, collaborations, or other transactions, or as to the timing of any of the foregoing.
SEEL Ratings Summary
SEEL Quant Ranking